Document Detail


Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
MedLine Citation:
PMID:  17564326     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The spectrum of CD30+ lymphoproliferative diseases of the skin includes CD30+ cutaneous anaplastic large cell lymphoma, lymphomatoidpapulosis, as well as borderline cases. These entities constitute the second most common group of cutaneous lymphomas according to the newly revised World Health Organization and European Organisation for Research and Treatment of Cancer consensus classification. Recent progress in immune and molecular biology, and identification of therapeutic targets have increased our understanding of these diseases and have led to novel treatment approaches. This review will provide an update on recent findings of immunologic, molecular, cytogenetic features and treatment strategies for patients with CD30+ lymphoproliferative diseases.
Authors:
Christiane Querfeld; Timothy M Kuzel; Joan Guitart; Steven T Rosen
Related Documents :
9557796 - Skin as the primary site of hodgkin's disease: a case report of primary cutaneous hodgk...
20571396 - Molecular signatures in the diagnosis and management of follicular lymphoma.
10797526 - Association of gastric and waldeyer's ring lymphoma: a molecular study.
9138616 - Management of cutaneous lymphoma.
16030936 - Experimental transmission of malignant catarrhal fever to red deer (cervus elaphus).
2493426 - Nutritional management of inflammatory bowel disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Oncology (Williston Park, N.Y.)     Volume:  21     ISSN:  0890-9091     ISO Abbreviation:  Oncology (Williston Park, N.Y.)     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-06-13     Completed Date:  2007-07-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712059     Medline TA:  Oncology (Williston Park)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  689-96; discussion 699-700,     Citation Subset:  IM    
Affiliation:
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois 60611, USA. c-querfeld@northwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD30 / metabolism
Combined Modality Therapy
Humans
Lymphoma, Large-Cell, Anaplastic / diagnosis,  pathology,  therapy
Lymphoma, T-Cell, Cutaneous* / diagnosis,  pathology,  therapy
Lymphomatoid Papulosis / diagnosis,  pathology,  therapy
Neoplasm Staging
Prognosis
Skin Neoplasms* / diagnosis,  pathology,  therapy
Chemical
Reg. No./Substance:
0/Antigens, CD30

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What progress have we made in managing inflammatory breast cancer?
Next Document:  Adjuvant therapy for pancreatic cancer: to treat or not to treat?